Interaction of the human prostacyclin receptor with the PDZ adapter protein PDZK1: Role in endothelial cell migration and angiogenesis

Molecular Biology of the Cell

Volumn 22, Issue 15, 2011, Pages 2664-2679

  Turner, Elizebeth C ^a   Mulvaney, Eamon P ^a   Reid, Helen M ^a   Kinsella, B Therese ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CICAPROST; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE A; PDZ DOMAIN CONTAINING PROTEIN 1; PDZ PROTEIN; PROSTACYCLIN RECEPTOR; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZYL COMPOUNDS; CARRIER PROTEINS; CELL MEMBRANE; CELL MOVEMENT; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; IMIDAZOLES; LIPOPROTEINS, HDL; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; PDZ DOMAINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION;

EID: 79961040974     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E11-04-0374     Document Type: Article

References (51)

1. Arehart E et al. (2008). Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res 102, 986-993. (Pubitemid 351591551)
2. Biscetti F et al. (2008). Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 57, 1394-1404.
3. Biscetti F et al. (2009). Peroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation. J Vasc Res 46, 103-108.
4. Biscetti F, Pola R (2008). Endothelial progenitor cells and angiogenesis join the PPARty. Circ Res 103, 7-9.
5. Clark RD, Jahangir A, Severance D, Salazar R, Chang T, Chang D, Jett MF, Smith S, Bley K (2004). Discovery and SAR development of 2-(phenylamino) imidazolines as prostacyclin receptor antagonists [corrected]. Bioorg Med Chem Lett 14, 1053-1056. (Pubitemid 38167641)
6. Davies SP, Reddy H, Caivano M, Cohen P (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351, 95-105.
7. Doyle DA, Lee A, Lewis J, Kim E, Sheng M, MacKinnon R (1996). Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell 85, 1067-1076. (Pubitemid 26231173)
8. Fenske SA, Yesilaltay A, Pal R, Daniels K, Barker C, Quinones V, Rigotti A, Krieger M, Kocher O (2009). Normal hepatic cell surface localization of the high density lipoprotein receptor, scavenger receptor class B, type I, depends on all four PDZ dmains of PDZK1. J Biol Chem 284, 5797-5806.
9. Fenske SA, Yesilaltay A, Pal R, Daniels K, Rigotti A, Krieger M, Kocher O (2008). Overexpression of the PDZ1 domain of PDZK1 blocks the activity of hepatic scavenger receptor, class B, type I by altering its abundance and cellular localization. J Biol Chem 283, 22097-22104.
10. Finn RD et al. (2010). The Pfam protein families database. Nucleic Acids Res 38, D211-D222.
11. Fitzgerald GA (2004). Coxibs and cardiovascular disease. N Engl J Med 351, 1709-1711.
12. Gorman CM, Gies D, McCray G (1990). Transient production of proteins using an adenovirus transformed cell line. DNA Protein Eng Tech 2, 3-10.
13. Gryglewski RJ (2008). Prostacyclin among prostanoids. Pharmacol Rep 60, 3-11.
14. Hayes JS, Lawler OA, Walsh MT, Kinsella BT (1999). The prostacyclin receptor is isoprenylated. Isoprenylation is required for efficient receptor-effector coupling. J Biol Chem 274, 23707-23718.
15. He T, Lu T, d'Uscio LV, Lam CF, Lee HC, Katusic ZS (2008). Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res 103, 80-88.
16. Hu S, Song E, Tian R, Ma S, Yang T, Mu Y, Li Y, Shao C, Gao S, Gao Y (2009). Systematic analysis of a simple adaptor protein PDZK1: ligand identification, interaction and functional prediction of complex. Cell Physiol Biochem 24, 231-242.
17. Jemth P, Gianni S (2007). PDZ domains: folding and binding. Biochemistry 46, 8701-8708. (Pubitemid 47204435)
18. Kato Y, Sai Y, Yoshida K, Watanabe C, Hirata T, Tsuji A (2005). PDZK1 directly regulates the function of organic cation/carnitine transporter OCTN2. Mol Pharmacol 67, 734-743. (Pubitemid 40365320)
19. Kawabe J, Ushikubi F, Hasebe N (2010a). Prostacyclin in vascular diseases. Recent insights and future perspectives. Circ J 74, 836-843.
20. Kawabe J et al. (2010b). Prostaglandin I2 promotes recruitment of endothelial progenitor cells and limits vascular remodeling. Arterioscler Thromb Vasc Biol 30, 464-470.
21. Kocher O, Comella N, Tognazzi K, Brown LF (1998). Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains. Lab Invest 78, 117-125. (Pubitemid 28074315)
22. Kocher O, Krieger M (2009). Role of the adaptor protein PDZK1 in controlling the HDL receptor SR-BI. Curr Opin Lipidol 20, 236-241.
23. Kocher O, Yesilaltay A, Cirovic C, Pal R, Rigotti A, Krieger M (2003). Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein metabolism. J Biol Chem 278, 52820-52825. (Pubitemid 38035880)
24. LaLonde DP, Bretscher A (2009). The scaffold protein PDZK1 undergoes a head-to-tail intramolecular association that negatively regulates its interaction with EBP50. Biochemistry 48, 2261-2271.
25. Lamprecht G, Seidler U (2006). The emerging role of PDZ adapter proteins for regulation of intestinal ion transport. Am J Physiol Gastrointest Liver Physiol 291, G766-G777. (Pubitemid 44772003)
26. Lawler OA, Miggin SM, Kinsella BT (2001a). The effects of the statins lovastatin and cerivastatin on signaling by the prostanoid IP-receptor. Br J Pharmacol 132, 1639-1649. (Pubitemid 32397955)
27. Lawler OA, Miggin SM, Kinsella BT (2001b). Protein kinase A-mediated phosphorylation of serine 357 of the mouse prostacyclin receptor regulates its coupling to G(s)-, to G(i)-, and to G(q)-coupled effector signaling. J Biol Chem 276, 33596-33607.
28. Lee HJ, Zheng JJ (2010). PDZ domains and their binding partners: structure, specificity, and modification. Cell Commun Signal 8, 8.
29. Li Z, Benard O, Margolskee RF (2006). Ggamma13 interacts with PDZ domain-containing proteins. J Biol Chem 281, 11066-11073. (Pubitemid 43855530)
30. Miggin SM, Lawler OA, Kinsella BT (2002). Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. Eur J Biochem 269, 1714-1725. (Pubitemid 34304471)
31. Miggin SM, Lawler OA, Kinsella BT (2003). Palmitoylation of the human prostacyclin receptorFunctional implications of palmitoylation and isoprenylation. J Biol Chem 278, 6947-6958. (Pubitemid 36800688)
32. Murata T et al. (1997). Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388, 678-682. (Pubitemid 27366439)
33. Nakamura T, Shibata N, Nishimoto-Shibata T, Feng D, Ikemoto M, Motojima K, Iso ON, Tsukamoto K, Tsujimoto M, Arai H (2005). Regulation of SR-BI protein levels by phosphorylation of its associated protein, PDZK1. Proc Natl Acad Sci USA 102, 13404-13409. (Pubitemid 41420860)
34. Navarro-Lerida I, Martinez-Moreno M, Ventoso I, Alvarez-Barrientos A, Rodriguez-Crespo I (2007). Binding of CAP70 to inducible nitric oxide synthase and implications for the vectorial release of nitric oxide in polarized cells. Mol Biol Cell 18, 2768-2777. (Pubitemid 47025741)
35. O'Keeffe MB, Reid HM, Kinsella BT (2008). Agonist-dependent internalization and trafficking of the human prostacyclin receptor: a direct role for Rab5a GTPase. Biochim Biophys Acta 1783, 1914-1928.
36. O'Meara SJ, Kinsella BT (2004a). Effect of the statin atorvastatin on intracellular signaling by the prostacyclin receptor in vitro and in vivo. Br J Pharmacol 143, 292-302.
37. O'Meara SJ, Kinsella BT (2004b). Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signaling by the prostacyclin receptor. Br J Pharmacol 143, 318-330.
38. O'Meara SJ, Kinsella BT (2005). The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signaling by the prostacyclin receptor. Biochem J 386, 177-189. (Pubitemid 40289238)
39. Patrignani P et al. (2008). Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. Pharmacogenet Genomics 18, 611-620.
40. Pola R, Gaetani E, Flex A, Aprahamian TR, Bosch-Marce M, Losordo DW, Smith RC, Pola P (2004). Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol 36, 363-370. (Pubitemid 38316941)
41. Qu Y, Shi X, Zhang H, Sun W, Han S, Yu C, Li J (2009). VCAM-1 siRNA reduces neointimal formation after surgical mechanical injury of the rat carotid artery. J Vasc Surg 50, 1452-1458.
42. Reid HM, Mulvaney EP, Turner EC, Kinsella BT (2010). Interaction of the human prostacyclin receptor with Rab11: characterization of a novel Rab11 binding domain within alpha-helix 8 that is regulated by palmitoylation. J Biol Chem 285, 18709-18726.
43. Reid HM, Wikstrom K, Kavanagh DJ, Mulvaney EP, Kinsella BT (2011). Interaction of angio-associated migratory cell protein with the TPalpha and TPbeta isoforms of the human thromboxane A(2) receptor. Cell Signal 23, 700-717.
44. Ribeiro LG, Brandon TA, Hopkins DG, Reduto LA, Taylor AA, Miller RR (1981). Prostacyclin in experimental myocardial ischemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality. Am J Cardiol 47, 835-840. (Pubitemid 11150926)
45. Tonikian R et al. (2008). A specificity map for the PDZ domain family. PLoS Biol 6, e239.
46. Turner EC, Kinsella BT (2010). Estrogen increases expression of the human prostacyclin receptor within the vasculature through an ERalpha-dependent mechanism. J Mol Biol 396, 473-486.
47. Voltz JW, Brush M, Sikes S, Steplock D, Weinman EJ, Shenolikar S (2007). Phosphorylation of PDZ1 domain attenuates NHERF-1 binding to cellular targets. J Biol Chem 282, 33879-33887. (Pubitemid 350159561)
48. Wang S, Yue H, Derin RB, Guggino WB, Li M (2000). Accessory protein facilitated CFTR-CFTR interaction, a molecular mechanism to potentiate the chloride channel activity. Cell 103, 169-179.
49. Wikstrom K, Reid HM, Hill M, English KA, O'Keeffe MB, Kimbembe CC, Kinsella BT (2008). Recycling of the human prostacyclin receptor is regulated through a direct interaction with Rab11a GTPase. Cell Signal 20, 2332-2346.
50. Yuhki K, Kojima F, Kashiwagi H, Kawabe J, Fujino T, Narumiya S, Ushikubi F (2011). Roles of prostanoids in the pathogenesis of cardiovascular diseases: novel insights from knockout mouse studies. Pharmacol Ther 129, 195-205.
51. Zhu W, Saddar S, Seetharam D, Chambliss KL, Longoria C, Silver DL, Yuhanna IS, Shaul PW, Mineo C (2008). The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity. Circ Res 102, 480-487. (Pubitemid 351651102)